

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

**Defective images within this document are accurate representations of the original documents submitted by the applicant.**

**Defects in the images may include (but are not limited to):**

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

Attorney Docket No.: **WARF-0003**  
Inventors: **Dickerson and Helfand**  
Serial No.: **09/801,485**  
Filing Date: **March 8, 2001**  
Page 5

#### **REMARKS**

Claims 1-9 are pending in the instant application. Claims 7-9 have been withdrawn from consideration by the Examiner and subsequently canceled without prejudice by Applicants in this amendment. Claims 1-6 have been rejected. Reconsideration is respectfully requested in light of the following remarks.

#### **I. Finality of Restriction Requirement**

The Examiner has made final the Restriction Requirement mailed March 26, 2003, agreeing however, to include Groups I and II in the instant application. Thus, in an earnest effort to advance the prosecution of this case, Applicants have canceled claims 7-9 without prejudice. In light of the finality of this Restriction Requirement, Applicants reserve the right to file a divisional application to the canceled subject matter.

#### **II. Objection to Title**

The Examiner has objected to the title suggesting that it is not descriptive of the invention to which the claims are directed. Thus, in an earnest effort to advance the prosecution of this case, Applicants have amended the title to be descriptive

Attorney Docket No.: WARF-0003  
Inventors: Dickerson and Helfand  
Serial No.: 09/801,485  
Filing Date: March 8, 2001  
Page 6

of the subject matter of the pending claims. Withdrawal of this objection is therefore respectfully requested.

### III. Rejection of Claims 1-6 under 35 U.S.C. § 103(a)

Claims 1-6 have been rejected under 35 U.S.C. § 103(a) as being unpatentable over Anderson (U.S. Patent 5,994,104) in view of Ruoslahti et al. (U.S. Patent 6,180,084). The Examiner suggests that it would have been obvious to one of ordinary skill in the art, at the time the invention was made to operably link interleukin-12 disclosed in Anderson et al. to a RGD-containing peptide protein described by Ruoslahti et al. to produce a fusion protein conjugate capable of binding to  $\alpha$ v-integrin receptors on the surface of tumor blood vessels sufficient to destroy the blood vessels and cause tumor necrosis because Anderson et al. teaches that a rIL-12 has potent anti-tumor effects and Ruoslahti et al. teach that chemotherapeutic agents linked to a tumor homing molecule are more efficacious than administration of the agent alone, in treating a tumor.

Applicants respectfully traverse this rejection.

MPEP § 2143 states that to establish a *prima facie* case of obviousness, three basic criteria must be met. First, there must

Attorney Docket No.: **WARF-0003**  
Inventors: **Dickerson and Helfand**  
Serial No.: **09/801,485**  
Filing Date: **March 8, 2001**  
Page 7

be some suggestion or motivation, either in the references themselves or in the knowledge generally available to one of ordinary skill in the art to modify the reference or combine the reference teachings. Second, there must be a reasonable expectation of success. Finally, the prior art references when combined must teach or suggest all the claim limitations. The cited combination does not meet these criteria.

As acknowledged by the Examiner, Anderson et al. does not teach interleukin-12 operably linked to a RGD-containing peptide that can be targeted to tumor cells. In fact, the fusion protein to which Anderson et al. refers is the fusion of two IL-12 subunits, not fusion of IL-12 to a different protein or peptide. Further, while there are teachings in Anderson et al. of coexpressing their IL-12 fusion protein with B7, there is no teaching or suggestion of creating a fusion protein of the IL-12 subunits and B7. Accordingly, this reference provides no motivation or suggestion to fuse an RGD-containing peptide to interleukin-12.

Ruoslahti et al. fails to remedy the deficiencies in the teachings of Anderson et al. since this reference also fails to provide any specific teaching or suggestion of fusion of IL-12 to a RGD-containing peptide.

---

Attorney Docket No.: **WARF-0003**  
Inventors: **Dickerson and Helfand**  
Serial No.: **09/801,485**  
Filing Date: **March 8, 2001**  
Page 8

Thus, there is no suggestion or motivation in the references themselves to combine their teachings.

Further, prior art teachings such as by Lieschke et al. (Nature Biotechnology 1997 15:35-40), a copy of which is provided herewith, show that activity of IL-12 is decreased in fusion proteins. Accordingly, the knowledge generally available to one of ordinary skill in the art teaches away from modifying these references or combining their teachings to produce a fusion protein of IL-12 and a RGD-containing peptide.

Further, neither the cited references nor what is known in the prior art (see e.g. Lieschke et al.) provide any reasonable expectation of success that a fusion protein of IL-12 operably linked to a RGD-containing peptide will maintain IL-12 anti-tumor activity or anti-angiogenic activity.

In addition, it has recently been demonstrated in references such as Reynolds et al. (Nature Medicine 2002 8:27-34), a copy of which is provided herewith, that  $\alpha v\beta 3$  and  $\alpha v\beta 5$  integrins are negative regulators of angiogenesis and that drugs targeting these receptors may act as agonists of angiogenesis as opposed to antagonists. Thus, if  $\alpha v\beta 3$  and  $\alpha v\beta 5$  block angiogenesis, binding of RGD would be expected to remove the negative regulation of  $\alpha v\beta 3$  and  $\alpha v\beta 5$ , thereby increasing vessel growth. Accordingly,

---

Attorney Docket No.: **WARF-0003**  
Inventors: **Dickerson and Helfand**  
Serial No.: **09/801,485**  
Filing Date: **March 8, 2001**  
Page 9

based upon information available to one skilled in the art, one would reasonably expect the IL-12vp fusion protein of the present invention to exhibit decreased anti-tumor activity as compared to IL-12 and either stimulate angiogenesis through the RGD moiety or to see little change when compared to IL-12 treated mice or cells since the RGD angiogenic activity would be expected to negate the IL-12 anti-angiogenic activity, at least to some extent. Thus, the demonstrated ability of the fusion protein of the present invention to inhibit angiogenesis and tumor growth is completely unexpected.

Thus, since the cited combination of prior art references and what is generally known in the prior art provide no suggestion or motivation to combine the reference teachings and the cited prior art teachings provide no reasonable expectation of success with respect to the instant claimed invention, the cited combination of prior art cannot render obvious the instant claimed invention.


Withdrawal of this rejection of claims 1-6 under 35 U.S.C. § 103(a) is therefore respectfully requested.

Attorney Docket No.: WARF-0003  
Inventors: Dickerson and Helfand  
Serial No.: 09/801,485  
Filing Date: March 8, 2001  
Page 10

#### IV. Conclusion

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record. Accordingly, favorable reconsideration and subsequent allowance of the pending claims is earnestly solicited.

Respectfully submitted,



Kathleen A. Tyrrell  
Registration No. 38,350

Date: November 12, 2003

LICATA & TYRRELL P.C.  
66 E. Main Street  
Marlton, New Jersey 08053  
(856) 810-1515

## RESEARCH

# Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo

Graham J. Lieschke<sup>1,2</sup>, Prakash K. Rao<sup>1,4</sup>, Maurice K. Gately<sup>2</sup>, and Richard C. Mulligan<sup>1,4,\*</sup>

<sup>1</sup>Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142; <sup>2</sup>Department of Infectious Diseases, Hoffmann-La Roche Inc., 340 Kingsland St., Nutley, NJ 07110-1192; <sup>3</sup>Present address: Ludwig Institute for Cancer Research, New York Unit at Memorial Sloan-Kettering Cancer Center, Box 32, 1275 York Avenue, New York, NY 10021; <sup>4</sup>Present address: Howard Hughes Medical Institute, Children's Hospital and Department of Genetics, Harvard Medical School, Boston, MA 02115. \*Corresponding author (e-mail: mulligan@rascal.med.harvard.edu).

Received 9 September 1996; accepted 26 November 1996

Interleukin-12 (IL-12) is unique amongst cytokines in being a disulfide-linked heterodimer of two separately encoded subunits (p35 and p40). We expressed single chain IL-12 proteins from retroviral constructs in which the two IL-12 subunits were linked by a 6–15 amino acid polypeptide linker, with deletion of the 22 amino acid leader sequence of the trailing subunit. The murine fusion protein IL-12.p40.L.Δp35 containing a (Gly,Ser)<sub>6</sub> linker was stably expressed, bioactive in vitro, and had an apparent specific activity comparable to that of native and recombinant IL-12. Western blotting confirmed that murine IL-12.p40.L.Δp35 retained the linking polypeptide sequences. The analogous human IL-12.p40.L.Δp35 fusion protein containing a (Gly,Ser)<sub>6</sub> linker was bioactive with an apparent specific activity comparable to recombinant human IL-12. In a preexisting CMS-5 tumor model, CMS-5 cells secreting either native or fusion protein forms of IL-12 prolonged survival and led to complete tumor regression.

**Keywords:** interleukin, cytokine, fusion protein, retrovirus, tumor immunotherapy

Interleukin-12 (IL-12) augments innate and cellular immunity in many ways potentially advantageous for the treatment of infectious and malignant disease<sup>1</sup>. Preclinical studies have evaluated the effects of systemic administration of recombinant IL-12 heterodimer<sup>2–4</sup> and initial clinical trials are in progress<sup>5</sup>. Alternative approaches have relied on genetic strategies for IL-12 production, using retroviral, adenoviral, and direct DNA gene transfer technologies. For example, fibroblasts and tumor cells transduced to secrete IL-12 have been shown to be highly effective therapies for preexisting tumors in several murine models<sup>6–8</sup>, and clinical studies of these genetically-based approaches have commenced<sup>9</sup>. However, the heterodimeric structure of IL-12 substantially complicates the construction of vectors for IL-12 production, because the expression of bioactive IL-12 requires expression of two separate genes and correct heterodimer assembly. This has previously been achieved in various ways: (1) cotransfection of two plasmids separately expressing each subunit gene<sup>10</sup>, (2) a single plasmid with IL-12 p35 and p40 expression cassettes in tandem array<sup>11</sup>, (3) by retroviruses containing internal ribosome entry site (IRES) sequences for the expression of both subunits from single polycistronic transcripts<sup>12–14</sup>, or (4) by a recombinant adenoviral vector with the subunit cDNAs separately inserted into early region 1 and E3 respectively<sup>15</sup>.

We now report the expression of a bioactive single chain murine IL-12 fusion protein (IL-12.p40.L.Δp35) with high specific in vitro bioactivity and which retained the potent antitumor activity of IL-12 in vivo. IL-12.p40.L.Δp35 comprised the p40 subunit linked by a (Gly,Ser)<sub>6</sub> linker to the p35 subunit from which the first 22 amino acids were deleted. The analogous human IL-12 fusion protein also retained high in vitro bioactivity.

## Results


**Expression of bioactive murine IL-12 fusion proteins.** A series of constructs were built in the SFG retroviral vector<sup>16</sup> for the expression of native murine IL-12 and IL-12 fusion proteins (Fig. 1A). SFG retroviral vectors containing either the IL-12 p35 or p40 cDNA (pSFG-IL-12.p35 and pSFG-IL-12.p40) were built for cotransfection or coinfection studies. For the expression of native IL-12 from a single retroviral vector, dicistronic SFG vectors were built with an internal ribosome entry site (IRES) sequence between the IL-12 p35 and p40 cDNAs (pSFG-IL-12.p35.IRES.p40 and pSFG-IL-12.p40.IRES.p35). For the expression of IL-12 fusion proteins, SFG vectors were built with the IL-12 p35 and p40 cDNAs linked in both orders, and with the presumed 22 amino acid secretory leader sequence deleted from the trailing cDNA (pSFG-IL-12.p35.L.Δp40 and pSFG-IL-12.p40.L.Δp35). The cDNAs were linked with a 45 base pair linker encoding the 15 amino acid (Gly,Ser)<sub>6</sub> linker of Huston et al.<sup>17</sup> The sequences encoding the linkers as successfully cloned are shown in Figure 1B.

Constructs were compared for their ability to direct bioactive IL-12 expression in a side-by-side screening experiment: CMS-5 tumor cells were infected with retroviruses generated by transfection of BOSC producer cells and medium conditioned by infected cells assayed for bioactive and immunoreactive IL-12 (Table 1). To standardize for possible differences in transfection and infection efficiency within this screening experiment, the dimensionless deduced parameter *relative specific activity* (ratio of ng/ml determined by bioassay and immunoassay) was calculated. This parameter standardizes the bioactivity to the amount of expressed protein, assuming equivalent immunoreactivity of all forms of IL-12 in the IL-12 p75 ELISA.





## RESEARCH




**Figure 2.** Western blot analysis of recombinant heterodimeric and fusion protein forms of murine IL-12 under non-reducing (A) and reducing (B) conditions. CM, conditioned medium; rmIL-12, recombinant murine IL-12;  $\beta$ -ME,  $\beta$ -mercaptoethanol. Dark arrow, p75 IL-12; gray arrow, p40 subunit. Construct designations are defined in Figure 1, and indicate the retroviruses used to infect cells for the preparation of native and fusion protein IL-12-containing conditioned media.

(designated pSFG.hIL-12.p40.L $\Delta$ p35). 3T3 cells were infected with SFG.hIL-12.p40.L $\Delta$ p35 retrovirus expressed transiently from transfected BOSC producer cells and conditioned medium collected and assayed for bioactive and immunoreactive human IL-12. Bioactive hIL-12 was produced with a specific activity of  $1.2 \times 10^6$  U/mg (mean of two determinations in parallel), compared to  $1.2$ – $2.0 \times 10^6$  U/mg for CHO cell-expressed recombinant hIL-12<sup>20</sup> (data not shown), although again, this comparison assumes equivalent immunoreactivity of the two IL-12 forms in the ELISA used for protein quantitation.

**In vivo antitumor activity of murine IL-12 fusion protein.** IL-12-expressing tumor cells have been reported to be effective therapy for preexisting tumors in several transplantable murine tumor models.<sup>2</sup> Hence we evaluated the relative in vivo anticancer activity of tumor cells transduced to express either native IL-12 (pSFG.IL-12.p35.IRES.p40) or the IL-12 fusion protein (with pSFG.IL-12.p40.L $\Delta$ p35).

Stable retrovirus producer clones were generated by transfection of pSFG.IL-12.p35.IRES.p40 and pSFG.IL-12.p40.L $\Delta$ p35 constructs into  $\psi$ -CRE and  $\psi$ -CRIP producer cells. Stable producer clones selected for their efficient transduction of 3T3 cells for IL-12 production were used to infect tumor cell populations in vitro. IL-12 secretion by tumor cell populations was measured by bioassay of conditioned media from irradiated transduced cells (Fig. 2). Infection of CMS-5 fibrosarcoma cells with  $\psi$ -CRE-IL-12 retrovirus resulted in secretion of high levels of native and fusion protein IL-12.  $\psi$ -CRIP-derived amphotropic retrovirus was necessary to achieve comparable levels of IL-12 secretion by B16 melanoma cells. (Assay of conditioned media from  $10^6$  non-irradiated cells documented equivalent or higher levels of IL-12 production.) Transfected unselected tumor cell populations maintained equivalent levels of native or fusion protein IL-12 production during 6 weeks of propagation in vitro, indicating that there was no significant negative selection against



**Figure 3.** Relative in vivo antitumor activity for established day 14 CMS-5 tumors treated with CMS-5 cells secreting either native or fusion protein forms of IL-12. (A) Kaplan-Meier survival plots for mice treated with  $5 \times 10^4$  wild type (thin line,  $n=24$ ), native IL-12-secreting (thick line,  $n=20$ ) or single-chain IL-12-secreting (broken line,  $n=20$ ) CMS-5 cells. (B) Titration of the relative in vivo antitumor activity of CMS-5 cells transduced to secrete either native or fusion protein forms of IL-12. Mice bearing 14-day tumors initiated with  $4 \times 10^4$  CMS-5 cells were treated with either  $10^5$  IL-12-secreting cells (Group 1), or  $5 \times 10^4$  cells of which 100, 20, 4, 0.8, 0.16 or 0% of cells were from the stock population of native or fusion protein IL-12-secreting CMS-5 cells (Groups 2–6 and C respectively). 20 mice per group except group 3 ( $n=25$ ) and control group C ( $n=24$ ); #,  $p=0.0003$ ; \*,  $p=0.004$ . Data are pooled from two separate experiments and survival was scored at day 162.

IL-12 secreting cells in vitro.

CMS-5 cells secreting either form of IL-12 were effective therapy for established CMS-5 tumors. Tumors were established with  $4 \times 10^4$  CMS-5 cells, resulting in a palpable tumor incidence of 90% on day 14 (median mean tumor diameter 4 mm; range 0–12.5 mm). Overall long-term survival of mice with CMS-5 tumors was 280% when cells transduced to secrete either form of IL-12 were administered in four weekly doses commencing on day 14, compared to 4% for control mice treated with wild-type tumor cells (Fig. 3A). Eighty-one percent of palpable tumors in mice treated with cells secreting IL-12 regressed completely, compared to 0% of tumors in control mice.

It was possible that there may have been a difference in the antitumor efficacy of IL-12-secreting cell populations that would be evident at submaximal levels of IL-12 secretion. Populations of tumor cells secreting different amounts of IL-12 were generated by mixing wild-type CMS-5 cells with diminishing proportions of IL-12-secreting cells and evaluated for therapeutic efficacy in mice with preexisting CMS-5 tumors (Fig. 3B). CMS-5 cells secreting p40.L $\Delta$ p35 IL-12 retained maximal in vivo antitumor

## RESEARCH

Table 2. Stable transduction of tumor cells for IL-12 production.

Tumor cell line	Retroviral producer cell line cell line/clone number	Provirus copy number	Bioactive IL-12 production $\mu\text{g}/10^6$ irradiated cells/ 48 hr (no. of assays)
CMS-5	nil	0	<0.0005 <sup>a</sup>
	CRE.IL-12.p35.IRES.p40/4	1.4	$4.24 \pm 0.73$ (34) <sup>a</sup>
	CAIE.IL-12.p40.L. $\Delta$ p35/43	0.5	$7.49 \pm 1.42$ (26) <sup>a</sup>
B16	nil	0	<0.0005 <sup>a</sup>
	CRE.IL-12.p35.IRES.p40/2	1.1	$0.057 \pm 0.002$ (3) <sup>a</sup>
	CAIP.IL-12.p35.IRES.p40/2	4.7	$1.10 \pm 0.26$ (9) <sup>a</sup>
	CAIP.IL-12.p40.L. $\Delta$ p35/22	1.8	$1.86 \pm 0.55$ (10) <sup>a</sup>
	CAIP.IL-12.p40.L. $\Delta$ p35/32	ND	$11.01 \pm 2.67$ (2) <sup>a</sup>

ND, not determined. Results from conditioned media assayed undiluted<sup>a</sup>, or diluted 1:100<sup>b</sup>, 1:1,000<sup>c</sup> or 1:10,000<sup>d</sup>.

activity when diluted 1:5 in wild-type cells (i.e., the treatment dose of  $5 \times 10^6$  CMS-5 cells comprised  $1 \times 10^6$  cells from the IL-12.p40.L. $\Delta$ p35-secreting population and  $4 \times 10^6$  wild-type CMS cells), whereas the cells secreting native IL-12 had only 50% of maximal in vivo antitumor activity at this dose level. However, since the p40.L. $\Delta$ p35 IL-12-secreting CMS-5 cells secreted 3–5 fold more IL-12 bioactivity than the native IL-12-secreting CMS-5 cells (based on in vitro bioassay of media conditioned by the cells used for the four treatment doses in these experiments), this difference was not evident when the data were standardized for the amount of secreted IL-12 bioactivity. No therapeutic difference was evident between cells secreting the two forms of IL-12 whether 1, 2, 3, or 4 weekly therapeutic doses of  $5 \times 10^6$  IL-12-secreting cells were administered.

## Discussion

We have described the expression of novel bioactive murine and human IL-12 fusion proteins. The murine fusion protein IL-12.p40.L. $\Delta$ p35 has a specific activity comparable to that of native and recombinant IL-12, and retains antitumor activity in vivo. The analogous human IL-12 fusion protein is also bioactive. Although the single chain IL-12 fusion proteins we describe resulted from an attempt to simplify the construction of retroviral vectors for IL-12 production, they potentially have wide additional application. The cDNAs encoding the human or mouse IL-12 fusion proteins circumvent the difficulties<sup>11,12</sup> of expressing two separate proteins to produce IL-12 and hence would be convenient for use in plasmid, adenoviral, and other expression systems under evaluation for cancer and infectious disease gene therapy. A particular theoretical advantage of single chain IL-12 expression is the elimination of the possibility of excess free p40 subunit synthesis, a potential problem since excess free p40 subunits have the capacity to form homodimers that function as specific IL-12 antagonists in both murine and human in vitro systems<sup>10,18</sup>. Furthermore, compared to native IL-12, the IL-12 fusion protein itself may have a different spectrum of relative potencies over the range of pleiotropic IL-12 activities, possibly resulting from a different affinity for IL-12 receptors, or from different pharmacobiology and pharmacokinetics in vivo, although we have not yet evaluated these possibilities. For the commercial manufacture of heterodimers such as IL-12, the large scale production of a single chain form may be simpler than that of the heterodimer, particularly because there is no need to include steps to purify the active moiety from contaminating subunit forms.

No initial presumption was made about the optimal order of components in the polypeptide backbone or the length of the linker, since there was no 3-dimensional structural information about IL-12 available at the outset. The (Gly,Ser)<sub>3</sub> linker of Huston et al.<sup>11</sup> was arbitrarily chosen for its flexibility<sup>19</sup>, and also because it

had been used previously in constructing single chain antibodies<sup>20</sup> and PIXY-321 (ref. 22), a linked form of human granulocyte macrophage colony stimulating factor and interleukin-3 already in clinical use. Cloning practicalities and a propensity for intra-linker deletion to occur during cloning influenced the final cDNA constructed for hIL-12.p40.L. $\Delta$ p35 (an intra-linker deletion also occurred in the construction of the PIXY-321 cDNA from the same linker sequence<sup>22</sup>). The basis of the different relative specific activities of the murine IL-12 fusion proteins expressed is likely to be structural, although the fusion protein did not alter the combination of sequences recently shown to be critical for the binding of murine p35 to the murine IL-12 receptor<sup>21</sup>. It is possible that the deletion of the leader sequence of the trailing cDNA might contribute to the relative potency and stability of the IL-12.p40.L. $\Delta$ p35 protein relative to some of the other numerous IL-12 fusion protein forms possible, by minimizing the bulk of nonessential sequences in this region of the otherwise correctly folded fusion protein, and by removing potential protease sites.

A potential disadvantage of incorporating an extraneous linker sequence in a therapeutic compound is that it may present immunogenic epitopes in vivo. The immunogenicity of the (Gly,Ser)<sub>3</sub> linker was not a consideration in its design for single chain antibodies and in vivo studies have been too limited for this to be known. The deletion variant linker Gly,SerGly,Ser in PIXY-321 (ref. 22) is also of unknown immunogenicity, although there is one preliminary report of antibody development and reduced efficacy of this compound with repeated administration<sup>24</sup>. However, the specificity of these antibodies has not been reported in detail and may have been against epitopes on either IL-3, GM-CSF, or the linker, and the presence of the powerful adjuvant GM-CSF in this fusion moiety may have unusually enhanced its inherent immunogenicity such as was seen with anti-idiotypic-GM-CSF fusion proteins<sup>25</sup>. An assessment of the immunogenicity of the IL-12 fusion proteins based on in vivo administration of purified recombinant material will be of interest.

The unselected populations of IL-12-producing tumor cells we made by infection with SFG-based retroviruses secrete 10–70 fold more IL-12 than the best achieved by others using IRES-containing retroviral constructs and selection for infected tumor cells<sup>20,23</sup>. The recently isolated producer CAIP.IL-12.p40.L. $\Delta$ p35/3 resulted in 900-fold greater IL-12 production by B16 cells than has previously been achieved for this tumor cell line<sup>4</sup>. Enrichment for infected cells by selection was not possible with our constructs since they did not contain a positive selectable marker, but our tumor cell populations averaged 0.5–4.7 proviral integrants per cell indicating high retroviral infectivity. Since we achieved high production of both native and single-chain IL-12, the difference is not explained by characteristics of the single chain IL-12 moiety per se although there was a trend for cells transduced to express the single chain IL-12 to secrete higher levels of IL-12 bioactivity despite lower rates of proviral integration.

With the high level of IL-12 secretion attained, we were able to demonstrate that the antitumor effect of IL-12-secreting CMS-5 cells exhibited a dose-response relationship in the preexisting CMS-5 tumor model, and that for survival and tumor regression endpoints the plateau of a dose-response relationship had been achieved. Notably, CMS-5 cells secreting a 25-fold reduction of IL-12 (extrapolated to be approximately 300 ng/10<sup>6</sup> irradiated cells/48 hr) had no in vivo antitumor activity. These observations are consistent with previous reports<sup>11,12</sup> indicating that high levels of IL-12 secretion may be required in some tumor models for antitumor effects to be seen, and suggest that where subtle or minimal effects have been observed in models using tumor cells secreting low amounts of IL-12, this may have resulted from a low level of IL-12 production.

The availability of murine and human single chain IL-12 fusion

prote-  
active  
ment  
for  
a  
tion  
viral

Experi-  
Cell line  
and C

Recom-  
p40 L.  
p35/3

The

ing  
three

and  
site

as pre-  
sense

(Gly,Ser)  
restriction

deletion

the

seen by  
by the

cause to  
present

in the

between

where

version

public

former

IL-12

cDNA

p40

as a

p35/3

of p35

show

site

p35/3

in

the



## RESEARCH

antibodies<sup>1</sup>  
cyte macro-  
ly in clinical  
er deletion  
constructed  
occured in  
ame linker  
activities of  
o be struc-  
bination of  
of murine  
he deletion  
ntribute to  
p35 protein  
tein form  
nces in this  
in, and by

eous linker  
t immune-  
Ser), linker  
ntibodies  
nown. The  
22) is also  
reliminary  
this com-  
ecificity of  
have been  
id the pre-  
oiety may  
uch as was  
assessment  
on in vivo  
of interest  
umor cells  
ere 10-70  
ing IRES-  
ted tumor  
LAp35/32  
s than has  
hment for  
construct  
r, but out-  
its per cell  
high pro-  
nce is not  
ety per se  
the single  
y despite

re able to  
ig CMS-5  
coexisting  
egression  
had been  
ion of IL-  
rradiated  
ervations  
igh levels  
for anti-  
minimal  
secreting  
v level of

IL-12 fusion

proteins of high specific in vitro bioactivity and potent antitumor activity in vivo provides an opportunity to expand the development of IL-12-based therapeutic strategies. This is particularly so for genetically-based strategies, since the cDNAs encoding these single chain forms of IL-12 substantially simplifies the construction of vectors for IL-12 production in plasmid, retroviral, adenoviral and other vector systems.

### Experimental protocol

**Cell lines.**  $\psi$ -CRIP<sup>+</sup>,  $\psi$ -CRE<sup>+</sup> and BOSC<sup>+</sup> producer cells, 3T3 cells, and B16<sup>+</sup> and CMS-5<sup>+</sup> tumor cell lines were propagated as previously described<sup>11</sup>.

**Retroviral vector construction.** Murine (m) and human (h) IL-12 p35 and p40 cDNA clones in pBluescript (Stratagene, La Jolla, CA) (pBS.IL-12.p35 and pBS.IL-12.p40) were a gift of Ueli Gubler (Hoffmann-La Roche, Nutley, NJ). These cDNAs corresponded to the published sequences<sup>12-14</sup>, except that the sequences of the murine p35 and murine and human p40 cDNAs surrounding the translational initiation ATG were changed to 5'-ACCATGG-3', in all three cases altering the second codon from TGT (cysteine) to GGT (glycine) and creating an NcoI restriction enzyme site. The internal ribosome entry site (IRES) sequence used was derived from the encephalomyocarditis virus<sup>15</sup> as previously used<sup>16</sup>. Linker sequences were synthesized as sense and anti-sense oligonucleotides spanning the sequence of Huston et al.<sup>17</sup> encoding the (Gly, Ser), linker, and adjacent sequences between convenient overhanging restriction enzyme sites in the 3' and 5' ends of the IL-12 subunit cDNAs, deleting the stop codon of the leading IL-12 subunit cDNA. Linker oligonucleotides were annealed, phosphorylated and ligated into dephosphorylated plasmids. In some cases, intra-linker deletions occurred during cloning (see Fig. 1B). The SFG retroviral vector used was derived from MFG<sup>18,19</sup> by the introduction of two point mutations which create an NheI site and cause the premature termination of the gag open reading frame sequences present in MFG (sequence details provided elsewhere<sup>11</sup>). SFG was propagated in the pUC19 plasmid and the cDNA inserts for expression were cloned between its unique NcoI and BamHI sites (the BamHI site was filled where necessary) using conventional techniques<sup>20</sup> (Fig. 1). Inserts in final versions of constructs were as follows (nucleotide numberings are from the published reports<sup>12-14</sup>): pSFG.IL-12.p35: p35 cDNA as a NcoI-EcoRI [filled] fragment of pBS.IL-12.p35; pSFG.IL-12.p40: p40 cDNA as a NcoI-BamHI [filled] fragment of pBS.IL-12.p40; pSFG.IL-12.p35.IRES.p40: p35 cDNA as a NcoI-EcoRI fragment of pBS.IL-12.p35, IRES cDNA as a EcoRI-NcoI fragment, p40 cDNA as a NcoI-BamHI fragment of pBS.IL-12.p40; pSFG.IL-12.p40.IRES.p35: p40 cDNA as a NcoI-BamHI fragment of pBS.IL-12.p40, IRES cDNA as a BamHI-NcoI fragment, p35 as a NcoI-EcoRI [filled] fragment of pBS.IL-12.p35; pSFG.IL-12.p35.LAp40: p35 cDNA from the NcoI site of pBS.IL-12.p35 to nt 771 (i.e., deleting the stop codon), linker as shown in Figure 1B(i), p40 cDNA from nt 101 to the EcoRI [filled] site of pBS.IL-12.p40 (i.e., deleting the first 22 codons of p40); pSFG.IL-12.p40.LAp35: p40 cDNA from the NcoI site of pBS.IL-12.p40 to nt 709 (i.e., deleting the stop codon), linker as shown in Figure 1B(ii), p35 cDNA from nt 193 to the EcoRI [filled] site of pBS.IL-12.p35 (i.e., deleting the first 22 codons of p35); SFG construct for the expression of human IL-12.p40.LAp35: hIL-12 p40 cDNA from the NcoI site of pBS.hIL-12.p40 to nt 997 (i.e., deleting the stop codon), linker as shown in Figure 1B(iii), hIL-12 p35 cDNA from nt 270 to the PpuMI [filled] site of pBS.hIL-12.p35 (i.e., deleting the first 22 codons of p35 following the second translational initiation codon). Constructs were sequenced across all cloning junctions to determine the nucleotide sequence of the linker and adjacent subunit regions.

**Expression of IL-12 proteins and collection of conditioned media.** For the side-by-side screening of a panel of constructs (Table 1), BOSC<sup>+</sup> producer cells were plated at  $2 \times 10^6$  cells per 6 cm tissue culture dish and transfected with the various constructs as previously described<sup>11</sup>.

Four hours after transfection, the medium was replaced with 5 ml of fresh medium. Virus-containing supernatants were collected 24 h later, filtered (0.45  $\mu$ m, Gelman Sciences, Ann Arbor, MI) and polybrene added (final concentration 8  $\mu$ g/ml). CMS-5 cells were infected with 2.5 ml of virus-containing supernatant for 4 h (CMS-5 cells had been plated at  $5 \times 10^4$  cells per 6 cm tissue culture dish the previous day). The remaining 2.5 ml of supernatant was frozen at -70°C and used for a second 4 h infection of the CMS-5 cells the following day. To collect IL-12-containing conditioned medium, the medium was replaced the following day with 5 ml fresh medium which was harvested 24 h later, filtered (0.2  $\mu$ m) and frozen at -70°C for later assay. The infected CMS-5 cells were then lysed, and genomic

DNA prepared for later analysis. For selected constructs, stably transfected  $\psi$ -CRE and  $\psi$ -CRIP producer clones<sup>11</sup> were generated as previously described<sup>11</sup>, screening individual producer clones for those with the greatest capacity to transduce 3T3 cells to produce bioactive IL-12. Retrovirus-containing supernatants from selected stable producer clones were used to infect tumor cell lines to generate populations of IL-12-secreting tumor cells. Tumors were transduced by four sequential 4 h infections in the presence of polybrene (8  $\mu$ g/ml). To facilitate infection of B16 cells with ecotropic  $\psi$ -CRE-derived retrovirus, pre-treatment with 2-deoxy-D-glucose was used according to a method developed by D. Lindemann (University of Würzburg, Germany, unpublished) based on observations of Kai et al.<sup>21</sup> For comparative determinations of IL-12 production by tumor cells (Table 2),  $10^6$  irradiated cells were plated in 10 ml of culture medium and conditioned media harvested after 18 h, filtered (0.2  $\mu$ m), and stored at -70°C until assayed.

**IL-12 bioassays and ELISAs.** Levels of IL-12 bioactivity in conditioned media (both serum-free and containing 10% fetal calf serum) were determined using the murine IL-12 splenocyte proliferative bioassay as described<sup>11</sup>. Samples were assayed at 1:1-1:10,000 dilutions and bioactivity determined in comparison to the linear part of a standard curve using recombinant murine (rm) IL-12 (gift of M. Gately, Hoffmann-La Roche) constructed over the range 20-5000 pg/ml rmIL-12 in the test sample. Curve fitting was performed using Deltagraph 4.0 (Deltapoint, Monterey, CA). All conditioned media samples contained demonstrable inhibitory activity; values reported were taken from the most dilute sample falling within the linear range of the standard curve, generally a 1:100 or 1:1,000 dilution. To calculate the relative specific activity (defined as the ratio of ng/ml determined by bioassay and immunoassay), a capture IL-12 bioassay was used as this was not complicated by the effects of inhibitory substances in conditioned media. Antibody capture bioassays and ELISA for murine and human IL-12 were performed as previously described<sup>11,22</sup>. The murine IL-12 p40 ELISA, which detects both heterodimeric and free p40, used the p40-specific 5D9 antibody to coat plates, whereas the heterodimer-specific mouse IL-12 p75 ELISA used the heterodimer-specific 9A5 antibody for coating. The mouse p40-specific antibody 5C3 was used in both ELISAs for detection of captured mouse IL-12 p40 or IL-12 p75. Anti-mouse IL-12 monoclonal antibodies were provided by D. Presky (Hoffmann-La Roche). A commercially available human IL-12 p75 ELISA (R&D Systems, Minneapolis, MN) was used for initial screening for human IL-12.p40.LAp35 production. Specific activity calculations for hIL-12.p40.LAp35 were based on bioactivity determinations in the antibody capture bioassay<sup>11</sup> and protein quantitation using the ELISA that employs the heterodimer-specific antihuman IL-12 antibody 20C2 as a capture antibody for human IL-12 p75<sup>23</sup>.

**Proviral copy number determination.** Proviral copy number was determined by Southern blot analysis<sup>24</sup>. Genomic DNA (10  $\mu$ g) digested by NheI was separated by electrophoresis in 0.8% agarose gels, transferred to a nylon membrane and separately probed with full-length <sup>32</sup>P-labelled IL-12 p35 or p40 cDNA fragments from pBS.IL-12.p35 and pBS.IL-12.p40, with validated stripping between hybridizations with each probe. Control lanes were based on 1 proviral copy in 10  $\mu$ g genomic DNA equalling 13.5 pg of pSFG.IL-12.p35.LAp40, and probe hybridization to the two endogenous genes served as a further internal control.

**Western blot analysis.** Serum-free conditioned media from wild-type CMS-5 cells or CMS-5 cells expressing native IL-12 or the IL-12 fusion protein were collected, filtered (0.2  $\mu$ m), and stored at -70°C. The conditioned media were concentrated 20-30 fold (Centricon 10, Amicon, Beverly, MA), and samples containing 20  $\mu$ g total protein run on separate 10% polyacrylamide gels with or without 10%  $\beta$ -mercaptoethanol. The primary antibody was a polyclonal goat anti-rmIL-12 antibody (gift of D. Presky, Hoffmann-La Roche), the secondary antibody a peroxidase-conjugated donkey anti-goat F(ab')<sub>2</sub> fragment at a 1:50,000 dilution (Jackson ImmunoResearch Labs, West Grove, PA), and the "Renaissance" detection system (DuPont NEN, Wilmington, DE) was used. A preliminary analysis indicated a fourfold-greater signal from conditioned media containing single chain IL-12 and therefore for the Western blot shown in Figure 2, 5  $\mu$ g total protein from this conditioned medium was loaded. The control lanes were conditioned media from wild-type cells without or spiked with 50 ng recombinant murine IL-12.

**In vivo tumor model.** The protocol was approved by the Massachusetts Institute of Technology Animal Care Committee. To initiate CMS-5 tumors, syngeneic 6-8 week old female BALB/c mice from Jackson Laboratories (Bar Harbor, ME) were injected with  $4 \times 10^5$  viable CMS-5 cells in 0.5 ml Hank's balanced salt solution (HBSS, Gibco, Grand Island, NY) subcutaneously on their back. On day 14, tumor size and incidence was documented

## RESEARCH

and a dose of  $5 \times 10^5$  irradiated (35 Gy,  $^{137}\text{Cs}$  source discharging 1.24 Gy/min) treatment cells administered subcutaneously in 0.5 ml HBSS in the left inguinal region. Treatment cells were wild-type CMS-5 cells, or unselected populations of CMS-5 cells transduced to express native IL-12 or the IL-12.p40.L.Δp35 fusion protein, or, for the experiment shown in Figure 3B, various mixtures of wild-type and IL-12 secreting cells. Treatment cells were administered to surviving mice weekly for 4 subcutaneous doses in alternating inguinal regions. Tumor size was monitored as the mean of two perpendicular tumor diameters, and mice were killed when the sum of two perpendicular tumor diameters exceeded 30 mm, or rarely, if tumors ulcerated (29.0% of non-survivors were sacrificed because of tumor bulk).

**Statistics.** Results are given as mean  $\pm$  standard error. JMP 3.1.5 software (SAS Institute, Cary, NC) was used for statistical analyses and construction of Kaplan Meier survival curves. Rare deaths due to incidental causes (e.g., failure to recover from anaesthetic) were treated as censored events for the construction of survival curves, but scored as non-survival in categorical classifications. Survival differences were evaluated with the Wilcoxon rank sum test, and the chi-squared test was used for categorical variables.

## Acknowledgments

We thank H. Bueler, D. Lindemann, D. Ory, M. Sadelain, and D. Sanders for helpful discussions; L.J. Huber for technical advice, and the following Hoffmann-La Roche scientists: Ueli Gubler for providing human and mouse IL-12 cDNAs; Frank Podlaski for providing human and mouse rIL-12 reference standards; Richard Chizzonite and David Presky for providing monoclonal antibodies against human and mouse rIL-12 for use in Western blots, ELISAs and antibody capture bioassays; and Rajeev Warrier and Daisy Carvajal for performing the IL-12 ELISAs and antibody capture bioassays. G.F. was a Howard Hughes Medical Institute Physician Postdoctoral Fellow, and was awarded the "Bushell Travelling Fellowship in Medicine or the Allied Sciences" for 1994 from the Royal Australasian College of Physicians. Supported in part by NCI grant CA-63399 to RCM.

1. Trinchieri, G. 1994. Interleukin-12: a cytokine produced by antigen-presenting cell with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. *Blood* 84:4008-4027.
2. Brunda, M.J., Luitre, L., Warrier, R.R., Wright, R.B., Hubbard, B.R., Murphy, M., et al. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. *J. Exp. Med.* 178:1223-1230.
3. Nastala, C.L., Edington, H.P., McKinney, T.G., Tahara, H., Nalesnik, M.A., Brunda, M.J., et al. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN- $\gamma$  production. *J. Immunol.* 153:1679-1706.
4. Wigginton, J.M., Komschlies, K.L., Beck, T.C., Franco, J.L., Brunda, M.J., and Wiltout, R.H. 1996. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. *J. Natl. Cancer Inst.* 88:38-43.
5. Jenks, S. 1986. After initial setback, IL-12 regaining popularity. *J. Natl. Cancer Inst.* 88:576-577.
6. Tahara, H., Zeh, H.J. III, Storkus, W.J., Pappo, I., Waykina, S.C., Gubler, U., et al. 1994. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. *Cancer Res.* 54:182-189.
7. Tahara, H., Zitvogel, L., Storkus, W.J., Zeh, H.J. III, McKinney, T.G., Schreiber, R.D., et al. 1995. Effective eradication of established murine tumors with IL-12 gene therapy using a polyclonal retroviral vector. *J. Immunol.* 154:6466-6474.
8. Zitvogel, L., Tahara, H., Robbins, P.D., Storkus, W.J., Clarke, M.R., Nalesnik, M.A., and Lopez, M.T. 1995. Cancer immunotherapy of established tumors with IL-12. *J. Immunol.* 155:1393-1403.
9. Rakhmilovich, A.L., Turner, J., Ford, M.J., McCabe, D., Sun, W.H., Sondel, P.M., et al. 1996. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. *Proc. Natl. Acad. Sci. USA* 93:6201-6206.
10. Zitvogel, L., Tahara, H., Cai, Q., Storkus, W.J., Muller, G., Wold, S.F., et al. 1994. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. *Hum. Gene Ther.* 5:1493-1506.
11. Martinotti, A., Stroppacciaro, A., Vagstad, M., Melani, C., Spreafico, F., Wysocka, M., et al. 1995. CD4 cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. *Eur. J. Immunol.* 25:137-148.
12. Colombo, M.P., Vagstad, M., Spreafico, F., Parenzo, M., Chiodoni, C., Melani, C., and Stroppacciaro, A. 1996. Amount of interleukin 12 available at the tumor site is critical for tumor regression. *Cancer Res.* 56:2531-2534.
13. Brameon, J., Hilt, M., Gallichan, W.S., Rosenthal, J.L., Gaudin, J., and Graham, F.L. 1995. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. *Hum. Gene Ther.* 7:333-342.
14. Bueler, H. and Mulligan, R.C. 1998. Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1. *Mol. Med.* 2:545-555.
15. Huston, J.S., Lavinson, D., Mudgett-Hunter, M., Tai, M.-S., Novotny, J.,

- Margolies, M.N., et al. 1988. Protein engineering of antibody binding sites: recovery of specificity activity in an anti-digoxin single-chain Fv analogue produced by *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* 85:5879-5883.
16. Martner, F., Fischer, S., Guckes, S., Jin, S., Kaufen, H., Schmitt, E., et al. 1993. The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-1 heterodimer. *Eur. J. Immunol.* 23:2202-2208.
17. Gillissen, S., Carvajal, C., Ling, P., Podlaski, F.J., Siremslo, D.L., Familletti, P.C., et al. 1995. Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. *Eur. J. Immunol.* 25:200-208.
18. Ling, P., Gately, M.K., Gubler, U., Stern, A.S., Lin, P., Hollfelder, K., et al. 1995. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. *J. Immunol.* 154:118-127.
19. Wu, C.Y., Demaree, C.E., Gately, M., Podlaski, F., Yssel, H., Kliniwa, M., and Delespessis, G. 1994. In vitro maturation of human neonatal CD4 T lymphocytes. I. Induction of IL-12-producing cells after long-term culture in the presence of IL-4 plus either IL-2 or IL-12. *J. Immunol.* 152:1141-1153.
20. Gately, M.K., Warrier, R.R., Honessaga, S., Carvajal, D.M., Feherty, D.A., Connaughton, S.E., et al. 1994. Administration of recombinant IL-12 to normal mice enhances cytotoxic lymphocyte activity and induces production of INF- $\gamma$  in vivo. *Int. Immunol.* 6:1257-1267.
21. Huston, J.S., McCartney, J., Tai, M.-E., Margolis-Harshorn, C., Jin, D., Warren, P., Kack, P., and Oppermann, H. 1993. Medical application of single-chain antibodies. *Intern. Rev. Immunol.* 10:195-217.
22. Currie, B.M., Williams, D.E., Broxmeyer, H.E., Dunn, J., Ferrah, T., Jeffrey, E., et al. 1991. Enhanced hematopoietic activity of a human granulocyte/macrophage colony-stimulating factor-interleukin 3 fusion protein. *Proc. Natl. Acad. Sci. USA* 88:5809-5813.
23. Zou, J.J., Schoenhaut, D.S., Carvajal, D.M., Warrier, R.R., Presky, D.H., Gately, M.K., and Gubler, U. 1995. Structure-function analysis of the p35 subunit of mouse interleukin 12. *J. Biol. Chem.* 270:5864-5871.
24. Miller, L.L., Korn, E.L., Stevens, D.S., Janik, J.E., Gause, B.L., Kopp, W.C., and Longo, D.L. 1996. Abrogation of the hematological activities of the GM-CSF/IL-3 fusion protein (PXY321) by anti-PXY321 antibodies in cancer patients receiving high-dose carboplatin: results of a phase I study. *Proc. Am. Soc. Clin. Oncol.* 14:1718 (Abstract 2012).
25. Chen, T.T. and Levy, R. 1995. Induction of autoantibody responses to GM-CSF by hyperimmunization with an Ig-GM-CSF fusion protein. *J. Immunol.* 154:3105-3117.
26. Dando, D. and Mulligan, R.C. 1988. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. *Proc. Natl. Acad. Sci. USA* 85:8460-8464.
27. Pear, W.S., Nolan, G.P., Scott, M.L., and Baltimore, D. 1993. Production of high-titer helper-free retroviruses by transient transfection. *Proc. Natl. Acad. Sci. USA* 90:8392-8396.
28. Fidler, I.J. 1976. Biological behavior of malignant cells correlated to their survival in vivo. *Cancer Res.* 35:218-234.
29. DeLeo, A.B., Shiku, H., Takahashi, T., John, M., and Old, L.J. 1977. Cell surface antigens or chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on culture fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. *J. Exp. Med.* 148:720-734.
30. Dranoff, G., Jaffee, E., Lazenby, A., Golumbs, P., Lavitsky, H., Brode, K., et al. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. *Proc. Natl. Acad. Sci. USA* 90:3530-3533.
31. Schoenhaut, D.S., Chua, A.O., Welitsky, A.G., Quinn, P.M., Dwyer, C.M., McComas, W., et al. 1992. Cloning and expression of murine IL-12. *J. Immunol.* 148:3433-3440.
32. Gubler, U., Chua, A.O., Schoenhaut, D.S., Dwyer, C.M., McComas, W., Motylka, R., et al. 1991. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. *Proc. Natl. Acad. Sci. USA* 88:4143-4147.
33. Wolf, S.F., Temple, P.A., Kobayashi, M., Young, D., Dicig, M., Lowe, L., et al. 1991. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. *J. Immunol.* 146:3074-3081.
34. Ghattas, I.R., Sane, J.R., and Majors, J.E. 1991. The oncoprotein entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and embryos. *Mol. Cell. Biol.* 11:5848-5859.
35. Frebourg, T., Sadelain, M., Ng, Y.-S., Kassal, J., and Friend, S.H. 1994. Equivalence of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. *Cancer Res.* 54:878-881.
36. Riviere, I., Brose, K., and Mulligan, R.C. 1995. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. *Proc. Natl. Acad. Sci. USA* 92:7633-7637.
37. Sambrook, J., Fritsch, E.F., and Maniatis, T. 1989. *Molecular cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, NY.
38. Kal, K., Salu, H., and Odaka, T. 1986. Relationship between the cellular resistance to Friend murine leukemia virus infection and the expression of murine leukemia virus gp70-related glycoprotein on cell surface of BALB/c-Fv-1w mice. *Viral.* 160:509-512.
39. Gately, M.K., Chizzonite, R., and Presky, D.H. 1995. Measurement of human and mouse interleukin 12, pp. 8.16.1-6.16.15 in *Current protocols in immunology*, volume 1. Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., and Strober, W. (eds.), John Wiley & Sons, New York.
40. Wilkinson, V.L., Warner, R.R., Trull, T.P., Nunes, P., Gately, M.K., and Presky, D.H. 1996. Characterization of anti-mouse IL-12 monoclonal antibodies and measurement of mouse IL-12 by ELISA. *J. Immunol. Methods* 189:15-24.

# Enhanced pathological angiogenesis in mice lacking $\beta_3$ integrin or $\beta_3$ and $\beta_5$ integrins

LOUISE E. REYNOLDS<sup>1</sup>, LORENZA WYDER<sup>1</sup>, JULIE C. LIVELY<sup>2</sup>, DANIELA TAVERNA<sup>2</sup>,  
STEPHEN D. ROBINSON<sup>1</sup>, XIAOZHU HUANG<sup>3</sup>, DEAN SHEPPARD<sup>3</sup>, RICHARD O. HYNES<sup>2</sup> &  
KAIRBAAN M. HODIVALA-DILKE<sup>1</sup>

<sup>1</sup>Cell Adhesion and Disease Laboratory, Richard Dumbleby Department, Imperial Cancer Research Fund, St. Thomas' Hospital, London, UK

<sup>2</sup>Howard Hughes Medical Institute, Center for Cancer Research, MIT, Cambridge, Massachusetts 02139, USA

<sup>3</sup>Lung Biology Center, University of California, San Francisco, California, USA

L.E.R. and L.W. contributed equally to this study.

Correspondence should be addressed to K.M.H.-D.; email: k.hodivala-dilke@icrf.icnet.uk

Inhibition of  $\alpha_v\beta_3$  or  $\alpha_v\beta_5$  integrin function has been reported to suppress neovascularization and tumor growth, suggesting that these integrins are critical modulators of angiogenesis. Here we report that mice lacking  $\beta_3$  integrins or both  $\beta_3$  and  $\beta_5$  integrins not only support tumorigenesis, but have enhanced tumor growth as well. Moreover, the tumors in these integrin-deficient mice display enhanced angiogenesis, strongly suggesting that neither  $\beta_3$  nor  $\beta_5$  integrins are essential for neovascularization. We also observed that angiogenic responses to hypoxia and vascular endothelial growth factor (VEGF) are augmented significantly in the absence of  $\beta_3$  integrins. We found no evidence that the expression or functions of other integrins were altered as a consequence of the  $\beta_3$  deficiency, but we did observe elevated levels of VEGF receptor-2 (also called Flk-1) in  $\beta_3$ -null endothelial cells. These data indicate that  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins are not essential for vascular development or pathological angiogenesis and highlight the need for further evaluation of the mechanisms of action of  $\alpha_v$ -integrin antagonists in anti-angiogenic therapeutics.


Angiogenesis, the formation of new blood vessels from pre-existing vasculature, involves coordinated endothelial-cell proliferation, migration and tube formation. This process is influenced both by growth factors, such as vascular endothelial growth factor (VEGF), and by cell adhesion molecules such as integrins<sup>1,2</sup>. Angiogenesis is a hallmark of cancer, as well as various ischemic diseases such as retinopathy of prematurity<sup>3</sup>, implying that anti-angiogenic drugs are likely to be of importance in the treatment of these diseases. Elucidating the precise molecular mechanisms of angiogenic regulation is therefore important in determining rational strategies for such anti-angiogenic approaches.

VEGF has been identified as a major angiogenic factor acting through endothelial cell-specific receptors, including VEGF receptor-2 (VEGFR-2; also called Flk-1)<sup>4</sup>. The importance of the VEGF/VEGFR-2 system in angiogenesis is supported strongly by the lack of vascular development and early embryonic lethality in mice both heterozygous for and deficient in VEGFR-2 (refs. 4–6). In many tumors and ischemic diseases, VEGF production is elevated, inducing adult pathological angiogenesis and further emphasizing the importance of VEGF in neovascularization. Strategies to block VEGF and VEGF receptor signaling and function have resulted in significant inhibition of tumor angiogenesis and such reagents are presently in clinical trials<sup>1,7,8</sup>. Several members of the integrin family are also implicated in angiogenesis<sup>9–18</sup>. The largest body of data has linked  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins (both receptors for vitronectin and other extracellular matrix molecules)

with blood-vessel development<sup>11–18</sup>. Particular attention has been paid to the role of  $\alpha_v\beta_3$  integrin in angiogenesis as it is prominent on proliferating vascular endothelial cells<sup>13,14</sup>. Furthermore, blockade of  $\alpha_v\beta_3$  integrin with monoclonal antibodies or low-molecular-weight antagonists inhibits blood-vessel formation in a variety of *in vivo* models<sup>17</sup>, including tumor angiogenesis<sup>11–13</sup> and neovascularization during oxygen-induced retinopathy<sup>19</sup>. In a recent report, a single small-molecule inhibitor of both  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins inhibited tumor angiogenesis in animal models<sup>20</sup>. Taken together, these inhibition data suggest critical roles for  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  in angiogenesis, and highlight their importance as potential targets in anti-angiogenic therapy. In fact, the  $\alpha_v\beta_3$ -integrin antagonist, Vitaxin, is presently in clinical trials<sup>21</sup>.

In contrast with these inhibitor studies, mice lacking  $\alpha_v$ ,  $\beta_3$  or  $\beta_5$  integrins exhibit extensive developmental angiogenesis<sup>22–24</sup>. All  $\alpha_v$ -null mice have extensive sprouting angiogenesis and develop normally until embryonic day 9.5 and approximately 20% of them survive to birth<sup>22</sup>.  $\beta_3$ -null mice are both viable and fertile and developmental angiogenesis, including postnatal neovascularization of the retina, appears to be  $\beta_3$ -independent<sup>23</sup>.  $\beta_5$ -null mice are also viable and fertile and have no defects in wound healing, suggesting that adult angiogenesis is unaffected in these animals<sup>24</sup>. These results indicate that the precise role of  $\alpha_v$  integrins in angiogenesis is likely to be more complex than initially thought and raise the question of the importance of  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins in adult pathological angiogenic processes. Using genetically defi-





**Fig. 1** Tumor growth and angiogenesis are enhanced in  $\beta_3$ -deficient mice. **a**, Measurement of murine B16F0 (left) and CMT19T (right) subcutaneous tumors grown in wild-type (□) and  $\beta_3$ -null (■) mice. Bars show mean tumor volume in mm<sup>3</sup>  $\pm$  s.e.m. for 10-day-old tumors. \*,  $P < 0.02$ ; \*\*,  $P < 0.01$ . **b**, Measurement of human A375SM s.c. tumors grown in Rag-2 (□) and Rag-2/ $\beta_3$ -null (■) mice. Bars show mean tumor weight in mg  $\pm$  s.e.m. for 36-day-old tumors. \*,  $P < 0.003$ . **c**, Macroscopic appearance of 10-day-old B16F0 (top) and CMT19T (bottom) tumors grown in wild-type (left) and  $\beta_3$ -null (right) mice. **d**, H&E-stained sections of B16F0 tumors from wild-type (left) and  $\beta_3$ -null (right) mice; microvessels (arrows) are clearly visible. **e**, VE-cadherin (top panels), laminin-1 (middle), and PECAM-1 (bottom) staining patterns in sections of B16F0 tumors from wild-type (left) and  $\beta_3$ -null (right) mice. Tumor vessels from  $\beta_3$ -null mice express all the endothelial markers tested. **f**, Microvessel density in B16F0 tumors was significantly greater in  $\beta_3$ -null (■) mice than in wild-type (□) mice (\*,  $P < 0.03$ ). **g**, In untreated skin sections vessel density was identical in wild-type (□) and  $\beta_3$ -null (■) mice. Scale bars: 1 cm (c); 50  $\mu$ m (d and e).

cient mice, we have tested the requirements for  $\beta_3$ , or the combination of  $\beta_3$  and  $\beta_5$  integrins, in adult neovascularization by monitoring pathological angiogenesis. Here we report the following results: 1) tumor growth and angiogenesis not only are supported, but were even enhanced in  $\beta_3$ -deficient and  $\beta_3/\beta_5$ -doubly deficient mice; 2) despite the parallel roles of  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  in angiogenesis,  $\alpha_v\beta_5$  and other integrins tested were not upregulated in response to  $\beta_3$  deficiency in endothelial cells; and 3) enhanced VEGF-induced angiogenic responses in  $\beta_3$ -null mice may be due, at least in part, to the elevated VEGFR-2 levels observed in  $\beta_3$ -deficient endothelial cells.

#### Tumor angiogenesis is enhanced in $\beta_3$ -deficient mice


Given that adult tumor angiogenesis can be inhibited by blockade of  $\alpha_v\beta_3$  integrin<sup>11–13,17</sup>, we investigated whether  $\beta_3$  deficiency had any effect on adult tumor angiogenesis.  $\beta_3$ -null and wild-type mice were injected subcutaneously with murine tumor cells; either melanoma (B16F0) or lung carcinoma (CMT19T) cells. As shown in Fig. 1a, tumors not only grew in both lines, but tumor size was enhanced significantly in the  $\beta_3$ -deficient mice when compared with controls ( $P < 0.02$  for B16F0 and  $P < 0.01$  for CMT19T). Representative examples of B16F0 and CMT19T tumors are shown in Fig. 1c. The growth of a human melanoma (A375SM) cell line was

also tested by subcutaneous injection into immunocompromised (Rag-2) mice and Rag-2/ $\beta_3$ -null mice (Fig. 1b). In concordance with the other tumor models, A375SM tumors were significantly larger in Rag-2/ $\beta_3$ -null mice ( $P < 0.003$ ) (Fig. 1b).

Sections of tumors were stained with hematoxylin and eosin (H&E). Microvessels were evident in tumors in both wild-type and  $\beta_3$ -null mice (Fig. 1d). Immunostaining with antibodies to various endothelial markers, including vascular endothelial (VE)-cadherin, laminin-1 and platelet endothelial-cell adhesion molecule-1 (PECAM-1) (Fig. 1e), VEGFR-2 and Tek (data not shown), established that the blood vessels in the  $\beta_3$ -null mice expressed all of the tested markers of endothelial cells. Blood-vessel density was quantified by counting the number of vessels per unit area across entire tumor sections.  $\beta_3$ -null mice had significantly elevated numbers of vessels per square millimeter of tumor when compared with wild-type controls ( $P < 0.03$ ) (Fig. 1f). Importantly, vessel density in non tumor-burdened adult scruff-skin was comparable between  $\beta_3$ -null and wild-type mice (Fig. 1g) suggesting that the enhanced tumor angiogenic response was not due to elevated blood-vessel density in untreated  $\beta_3$ -null skin.

#### $\beta_3/\beta_5$ -deficient mice have enhanced tumor angiogenesis

Because  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins are related receptors and are both thought to be involved in angiogenesis<sup>15,20</sup>, it is possible




**Fig. 2**  $\beta_3/\beta_5$ -null mice show enhanced tumor growth and angiogenesis. **a**, Measurement of B16F0 (left) and CMT19T (right) s.c. tumors in wt ( $\square$ ) and  $\beta_3/\beta_5$ -null ( $\blacksquare$ ) mice. The mean tumor volume in  $\text{mm}^3 \pm \text{s.e.m.}$  is given for 10-day-old tumors. \*,  $P < 0.05$ ; \*\*,  $P < 0.007$ . **b**, Measurement of human LS180 s.c. tumors grown in Rag-2 ( $\square$ ) and Rag-2/ $\beta_3/\beta_5$ -null ( $\blacksquare$ ) mice. The mean tumor weight in  $\text{mg} \pm \text{s.e.m.}$  is presented for 21-day-old LS180 tumors (\*,  $P < 0.003$ ). **c**, Macroscopic appearance of 10-day-old B16F0 (top) and CMT19T (bottom) tumors grown in control (left) and  $\beta_3/\beta_5$ -null (right) mice. **d**, In H&E-stained

sections of tumors from  $\beta_3/\beta_5$ -null mice microvessels are clearly visible (arrows). **e**, Microvessels were detected by PECAM immunostaining of tumors in control (left) and  $\beta_3/\beta_5$ -null (right) mice. **f**, Microvessel density in B16F0 tumors was significantly higher in  $\beta_3/\beta_5$ -null ( $\blacksquare$ ) mice than in wild-type ( $\square$ ) mice. \*,  $P < 0.008$ . **g**, In untreated skin sections vessel density was the same in wild-type ( $\square$ ) and  $\beta_3/\beta_5$ -null ( $\blacksquare$ ) mice. Scale bars: 1 cm (**c**); 50  $\mu\text{m}$  (**d** and **e**).


that in the absence of both  $\beta_3$  and  $\beta_5$  integrins angiogenesis would be completely blocked. To test this, we examined subcutaneous B16F0 and CMT19T tumors in  $\beta_3/\beta_5$ -doubly deficient mice. Results showed that tumor growth was not only supported in these mice, but also that tumors were significantly larger when compared with controls (Fig. 2a). Similarly, subcutaneous growth of colon carcinoma (LS180) in Rag-2/ $\beta_3/\beta_5$ -null mice was significantly enhanced compared with controls ( $P < 0.014$ ) (Fig. 2b). Representative ex-

amples of B16F0 and CMT19T tumors are shown in Fig. 2c. Histological analysis of an H&E-stained tumor section (Fig. 2d) and immunodetection of PECAM-1 (Fig. 2e), VE-cadherin, laminin-1 and VEGFR-2 (data not shown) revealed that angiogenic blood vessels were clearly detectable in the  $\beta_3/\beta_5$ -null mice. Moreover, tumors from these mice were significantly hyper-vascularized when compared with controls ( $P < 0.008$ ) (Fig. 2f). In contrast, blood-vessel density in unchallenged  $\beta_3/\beta_5$ -null skin was comparable to control skin



**Fig. 3**  $\beta_3$  deficiency does not affect the expression or function of other integrins. **a**, Surface iodination and immunoprecipitation of  $\beta_3$ ,  $\alpha_v$ ,  $\beta_5$ ,  $\beta_1$ ,  $\alpha_1$ ,  $\alpha_2$  and  $\alpha_5$  integrin subunits from lung-derived wild-type (wt) and  $\beta_3$ -null ( $-/-$ ) endothelial cells. **b**, Immunofluorescence staining of wild-type and  $\beta_3$ -null endothelial cells stained with antibodies to  $\beta_3$ ,  $\alpha_v$ ,  $\beta_1$  and  $\alpha_5$ .  $\beta_3$ -subunit was absent and  $\alpha_v$ -subunit was reduced in  $\beta_3$ -null endothelial-cell focal contact sites. Scale bar: 5  $\mu\text{m}$ . **c** and **d**, In adhesion assays (**c**), and migration assays (**d**),  $\beta_3$ -null endothelial cells had background activity on vitronectin (VN), but responses on fibronectin (FN), collagen (COLL) and laminin-1 (LM-1) were normal. Adhesion and migration values are given as mean percentages  $\pm \text{s.e.m.}$  relative to wild-type cell activity on FN. \*,  $P < 0.003$ ; \*\*,  $P < 0.000007$ .  $\square$ , wild-type cells;  $\blacksquare$ ,  $\beta_3$ -null cells.





**Fig. 4** Hypoxia-induced retinal angiogenesis is enhanced in  $\beta_3$ -null mice. **a**, Flat mounts of retinas from wild-type (left) and  $\beta_3$ -null (right) mice that have undergone hypoxia-induced retinal angiogenesis show extensive areas of neovascularization with excessive development of vascular glomeruli (arrowheads) in the  $\beta_3$ -null retinas. **b**, Quantification of vascular glomeruli in wild-type ( $\square$ ) and  $\beta_3$ -null ( $\blacksquare$ ) retinas ( $n = 9$ – $12$  mice per genotype; \*,  $P < 0.02$ ). **c**, Cross-sections of eyes from wild-type (left) and  $\beta_3$ -null (right) mice showing retinal neovascularization internal to the inner limiting membrane in both genotypes (arrowheads) with excessive development of vascular glomeruli in the  $\beta_3$ -null retinas (arrows). V, vitreous; ILM, inner limiting membrane; GCL, ganglion cell layer; IPL, inner plexiform layer. Scale bars: 100  $\mu\text{m}$  (a); 50  $\mu\text{m}$  (c).

(Fig. 2g). Thus, our data provide strong evidence that deficiency of either  $\beta_3$  alone, or both  $\beta_3$  and  $\beta_5$  integrins, can enhance tumor growth and angiogenesis. These data demonstrate that  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins are not essential for tumor angiogenesis.

#### $\beta_3$ deficiency does not affect other integrin subunits


Apart from the two receptors,  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$ , other integrins

such as the fibronectin receptor  $\alpha_5\beta_1$  and the collagen receptors  $\alpha_2\beta_1$  and  $\alpha_1\beta_1$  have also been suggested to play roles in angiogenesis<sup>9–14,25</sup>. This raises the possibility that other integrins may compensate for  $\beta_3$  deficiency. We compared the expression profiles and functions of integrins in wild-type and  $\beta_3$ -null endothelial cells. Surface iodination followed by immunoprecipitation of  $\beta_3$  and  $\alpha_v$  integrins showed a complete loss of  $\beta_3$  integrin and reduced levels of  $\alpha_v$  integrin in the  $\beta_3$ -null endothelial cells. However, no changes in surface expression of  $\beta_5$ ,  $\beta_1$ ,  $\alpha_1$ ,  $\alpha_2$  or  $\alpha_5$  integrins were detected by surface iodination and immunoprecipitation (Fig. 3a). Western-blot analysis also showed no difference in total  $\beta_5$ -subunit levels in endothelial cells (data not shown). Focal contact distribution of integrins in the  $\beta_3$ -null endothelial cells was examined by immunofluorescence using antibodies to various integrins, including  $\beta_3$ ,  $\alpha_v$ ,  $\beta_1$  and  $\alpha_5$  integrins. Apart from the absence of detectable  $\beta_3$  integrin in the  $\beta_3$ -null endothelial cells,  $\alpha_v$  expression appeared to be somewhat reduced and there were no changes in  $\beta_1$  or  $\alpha_5$  integrin patterns (Fig. 3b).


To test whether the loss of  $\beta_3$  integrins had any effect on the functions of other integrins, we performed adhesion and migration assays on fibronectin, collagen, laminin-1 and vitronectin. In adhesion assays, wild-type and  $\beta_3$ -null endothelial cells adhered equally well to fibronectin, collagen and laminin-1. In contrast to wild-type cells,  $\beta_3$ -null cells showed background levels of adhesion to vitronectin (Fig. 3c). In migration assays,  $\beta_3$ -null endothelial cells had normal migratory abilities on most substrates, but migration was ablated on vitronectin (Fig. 3d). These data show no evidence for compensation by other integrins in response to  $\beta_3$  deficiency.


#### $\beta_3$ deficiency enhances VEGF-induced blood-vessel growth

Since  $\beta_3$ -null mice exhibited enhanced tumor angiogenesis, we sought to investigate the effect of  $\beta_3$  deficiency in another adult neovascularization assay. Hypoxia-induced retinal neovascularization in neonatal mice is a model for the ischemic disease retinopathy of prematurity, and it provides a useful



**Fig. 5**  $\beta_3$  deficiency enhances VEGF-induced vessel growth *in vivo* and *in vitro*. **a**, Quantification of microvessels infiltrating Matrigel implants in wild-type ( $\square$ ) or  $\beta_3$ -null ( $\blacksquare$ ) mice in the presence or absence of VEGF shows augmented VEGF-induced angiogenesis in the  $\beta_3$ -null mice compared with VEGF-induced angiogenesis in wild-type mice. \*,  $P < 0.05$ . VEGF-induced angiogenesis in wild-type mice was significantly enhanced compared with PBS controls. \*\*,  $P < 0.015$ . **b**, In *ex vivo* aortic ring assays microvessel numbers were counted from wild-type ( $\square$ ) and  $\beta_3$ -null ( $\blacksquare$ ) aortic rings grown in the presence of DMEM (left panel), FCS (middle) or VEGF (right).  $\beta_3$ -null samples had elevated angiogenic responses to VEGF ( $n = 5$ – $7$  mice per genotype; \*,  $P < 0.05$ ). **c**, Low-power light micrographs of representative wild-type (left) and  $\beta_3$ -null (right) aortic ring microvessels grown in the presence of VEGF.





**Fig. 6** Enhanced VEGFR-2 expression on  $\beta_3$ -null endothelial cells. **a**, Flow-cytometric analysis of VEGFR-2 surface-expression levels showed that  $\beta_3$ -null (right) endothelial cells expressed significantly higher levels of VEGFR-2 relative to wild-type controls (left). Bold line, VEGFR-2-labeled cells; thin line, negative control. Bar chart shows means  $\pm$  s.e.m. of relative surface VEGFR-2 expression in wild-type ( $\square$ ) and  $\beta_3$ -null ( $\blacksquare$ ) endothelial cells compared with negative control ( $n = 3$ ; \*,  $P < 0.014$ ). **b**, Western-blot analysis of VEGFR-2 levels in wild-type and  $\beta_3$ -null endothelial cells that were either grown in culture or isolated from tumors directly. Bar charts represent densitometry results (means  $\pm$  s.e.m.) from 2–4 independent experiments that show that  $\beta_3$ -null ( $\blacksquare$ ) endothelial cells express 2–3-fold more VEGFR-2 than wild-type controls ( $\square$ ). Western blotting for HSC-70 provided loading controls. **c**,  $\beta_3$ -null endothelial cells were infected with control retrovirus (mock), or with virus containing human  $\beta_3$  integrin ( $\beta_3.1$ ) and mock-infected wild-type cells were used as controls. Western-blot analyses confirmed that  $\beta_3$  levels were restored in  $\beta_3$ -null cells infected with  $\beta_3.1$ . In  $\beta_3$ -null cells infected with  $\beta_3.1$ , VEGFR-2 expression was reduced to wild-type levels. Western blotting for HSC-70 provided loading controls. Bar charts represent densitometry results (means  $\pm$  s.e.m.,  $n = 3$ ) of relative  $\beta_3$  integrin and VEGFR-2 levels.

might be elevated in  $\beta_3$ -deficient mice. Matrigel implants impregnated with VEGF or PBS (in the presence of heparin<sup>44</sup>) were administered subcutaneously to wild-type and  $\beta_3$ -null mice and blood-vessel infiltration of the implants was quantified. In contrast to PBS controls, VEGF induced angiogenic responses in both wild-type and  $\beta_3$ -null mice and this response was significantly elevated in  $\beta_3$ -null mice when compared with controls (Fig. 5a). Further analysis of VEGF-induced neovascularization responses was carried out using *ex vivo* aortic ring assays. Wild-type and  $\beta_3$ -null aortic rings were embedded in Matrigel in the presence or absence of serum or VEGF and the numbers of vascular sprouts

per aortic ring over a period of 14 days in culture were assessed. In the absence of serum or VEGF, very little vessel outgrowth was detected in either wild-type or  $\beta_3$ -null samples, whereas serum induced neovascularization to a similar extent in both. However, in the presence of VEGF, the total number of vessel sprouts was significantly higher for  $\beta_3$ -null samples when compared with wild-type controls ( $P < 0.05$ ) (Fig. 5b). Representative micrographs of vessels sprouting from aortic rings grown in the presence of VEGF are shown in Fig. 5c.

method to quantify neovascularization in  $\beta_3$ -null mice. Postnatal day 7 (P7) mice were placed in 75% oxygen for five days causing central avascularization of both wild-type and  $\beta_3$ -null retinas (data not shown). This incubation was followed by housing the mice for five further days (until P17) under normoxic conditions after which neovascularization was detected by perfusion of the entire vasculature with a non-diffusible fluorescein-dextran solution. In flat-mounted wild-type and  $\beta_3$ -null retinas, we detected areas of neovascularization and vascular glomeruli (Fig. 4a). Vascular glomeruli are highly proliferative clusters of tortuous vessels that are produced in response to angiogenic stimuli and protrude through the inner limiting membrane. The numbers of glomeruli were counted to compare retinal neovascularization in wild-type and  $\beta_3$ -null mice. We observed significantly elevated numbers of vascular glomeruli in  $\beta_3$ -null mice at P17 (Fig. 4a and b) and in retinal cross-sections (Fig. 4c). These data provide evidence that  $\beta_3$ -null mice show enhanced neovascularization not only in tumors but also in hypoxia-induced retinopathy.

VEGF expression is elevated in hypoxia-induced retinal angiogenesis and is thought to be the major angiogenesis-stimulating factor in this system<sup>26,27</sup>. Because hypoxia-induced retinal neovascularization was enhanced in the  $\beta_3$ -null mice, we hypothesized that VEGF-stimulated angiogenesis per se

#### Elevated VEGFR-2 levels in $\beta_3$ -null endothelial cells

Since  $\beta_3$ -null mice had elevated responses to VEGF, we tested whether the  $\beta_3$ -null endothelial cells had elevated levels of VEGFR-2. Flow cytometric analysis showed that  $\beta_3$ -null endothelial cells expressed significantly higher levels of surface VEGFR-2 than wild-type control endothelial cells ( $P < 0.014$ ) (Fig. 6a) and densitometric analyses of western blots approximately three-fold more total VEGFR-2 (Fig. 6b). In addition, tumor-derived endothelial cells from  $\beta_3$ -null mice also had elevated levels of total VEGFR-2 (Fig. 6b). Tumor-derived endothelial cells from wild-type and  $\beta_3$ -null mice both had consistently elevated total VEGFR-2 levels when compared with lung-derived endothelial cells. Moreover, we showed that transduction of  $\beta_3$ -null endothelial cells with human  $\beta_3$  integrin not only in-

duced  $\beta_3$  expression in these cells, but also reduced the aberrant levels of VEGFR-2 to wild-type levels (Fig. 6c), suggesting that  $\beta_3$  integrin can regulate VEGFR-2 expression.

### Discussion

Our observations, that  $\beta_3$ -null or  $\beta_3/\beta_5$ -null mice not only support tumor angiogenesis and tumor growth, but even exhibit augmented responses, were unexpected and call for a reconsideration of the functions of  $\alpha_v$  integrins in angiogenesis.

The integrin receptors,  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$ , have been implicated in angiogenesis by their expression in vascular sprouts and by experiments blocking angiogenesis stimulated by growth factors, by tumors<sup>11-13</sup> or in hypoxia-induced retinal angiogenesis<sup>16,19</sup>. These data have been interpreted to suggest that antagonists of  $\alpha_v\beta_3$  integrin inhibit angiogenesis by blocking its ligand-binding functions with consequences such as reduced proliferation and migration and increased apoptosis of endothelial cells<sup>11-18</sup>. Thus  $\alpha_v\beta_3$  integrin has been thought to be essential for both developmental and pathological angiogenesis, and this has led to the generation of  $\alpha_v\beta_3$  antagonists as potential anti-angiogenic therapeutics<sup>21</sup>.

However, it is also known that mice lacking  $\alpha_v$  integrins<sup>22</sup> and others deficient in  $\beta_3$  or  $\beta_5$  integrins<sup>24,25</sup>, can support developmental angiogenesis. What was not known thus far is whether the absence of these integrins has any impact on pathological angiogenesis. In contrast with the inhibitor data, our results show not only that neither  $\alpha_v\beta_3$  nor  $\alpha_v\beta_5$  integrin is required for such angiogenesis, but also that, in their absence, there is an increased angiogenic response. Furthermore, the enhanced angiogenic responses in the  $\beta_3$ -null and  $\beta_3/\beta_5$ -null mice lead to enlarged tumors, again in marked contrast with the blocking data where  $\alpha_v\beta_3$  antagonists inhibit tumor growth. Our *in vivo* findings appear to be supported by recent *in vitro* observations that  $\alpha_v\beta_3$  antagonists enhance the differentiation of endothelial cells into tubes<sup>28</sup>. In order to generate vessels, endothelial cells need to proliferate, survive and migrate into avascular tissue. As discussed above, these processes were previously thought to be dependent on  $\alpha_v\beta_3$  integrin, but our data indicate that this is not the case. How can these discrepancies between the blocking and genetic ablation data be explained?

A first possibility is that genetic ablation underestimates the importance of  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins because of some sort of compensatory response by other adhesion molecules. We failed to detect upregulation in levels or activities of other integrins including  $\alpha_v\beta_5$  in  $\beta_3$ -null endothelial cells. Additionally,  $\beta_3/\beta_5$ -null mice show the same enhanced tumor growth and angiogenesis as do  $\beta_3$ -null mice. This indicates that  $\alpha_v\beta_5$  integrin is unlikely to compensate for the absence of  $\alpha_v\beta_3$  integrin and that neither  $\alpha_v\beta_3$  nor  $\alpha_v\beta_5$  integrin are essential in angiogenesis. However, other mechanisms of compensation cannot be ruled out.

A second possible explanation for the discrepancy is that the blocking experiments may overestimate the contributions of  $\alpha_v\beta_3$  in angiogenesis. Assessment of the impact of known  $\alpha_v\beta_3$  antagonists such as LM609 (ref. 17) in  $\beta_3$ -null and wild-type mice would be of great interest. However, LM609 does not react with mouse  $\alpha_v\beta_3$  and thus use of peptide antagonists may better address specificity of these reagents in future studies. Cross-talk between  $\alpha_v\beta_3$  and other integrins such as  $\alpha_5\beta_1$  has been suggested to affect angiogenesis<sup>10,25</sup>. Trans-dominant

inhibition of other integrins by interference with  $\beta_3$  integrins has also been demonstrated<sup>29</sup>. In fact, cross-talk among integrins is a well established phenomenon<sup>30-33</sup>. Based on these prior results, it is possible that the antibodies and low-molecular-weight antagonists of integrins, however specific they are, could be inhibiting other integrins, or even other functions, indirectly. Blocking and other experiments have highlighted the importance of  $\alpha_5$ ,  $\alpha_1$  and  $\alpha_2$  in angiogenesis<sup>10,12-14,25,34</sup> and it is clear that  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  are not the only integrins involved in angiogenesis.

A third possible explanation could be an altered mechanism of angiogenesis in the  $\beta_3$ -null mice. Recent data have indicated that in pathological angiogenesis, some endothelial cells in newly formed blood vessels can originate from bone marrow-derived stem cells<sup>35-38</sup>. The differences between  $\alpha_v\beta_3$  blocking and genetic ablation results may relate to differences in stem-cell mobilization. Notably, in a recent study of placental growth factor (PlGF)-deficient mice, developmental angiogenesis was normal, but loss of PlGF impaired pathological angiogenesis. Here the differences were attributed to inhibition of mobilization of bone marrow-derived endothelial cells in the PlGF-null mice<sup>39</sup>. While mobilization of bone marrow could be enhanced in  $\beta_3$ -null mice, such a possibility would not explain our *ex vivo* results and the precise mechanism would require further elucidation especially concerning the role of VEGFR-2. An alternative mechanism is that absence of  $\alpha_v$  integrins could compromise recruitment of leukocytes and that this in turn could allow faster tumor growth.

Our observation that tumors are actually larger in mice lacking  $\alpha_v\beta_3$  or both  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins and that angiogenesis is actually enhanced in these mice suggest that, rather than being required for angiogenesis, these integrins might normally have a role in limiting angiogenesis *in vivo*. To cite one potential example, during the growth of new vessels, ligated and unligated integrins might provide positive and negative signals for endothelial cell growth and/or survival, only allowing the formation of vessels in the presence of appropriate extracellular matrix ligands. Integrin antagonists could then mimic the unligated state and inhibit vessel growth. In this scenario, the absence of these integrins would result in a loss of the negative signals and could lead to enhanced angiogenesis, as we observed.

Our observation of elevated levels of VEGFR-2 expression on  $\beta_3$ -null endothelial cells suggests one mechanism by which  $\alpha_v\beta_3$  integrin could negatively regulate angiogenesis. On the one hand, this could simply be some kind of angiogenic compensatory response to the absence of  $\beta_3$  integrins; on the other hand, this result could reflect a mechanism normally in play. Indeed, these two possibilities could represent two aspects of the same mechanism. Interactions between  $\beta_3$  integrins and VEGFR-2 have been reported<sup>40,41</sup>. If a normal function of  $\alpha_v\beta_3$  (and perhaps also  $\alpha_v\beta_5$ ) integrin were regulation of the VEGF/VEGFR-2 signaling pathway, then absence of  $\alpha_v\beta_3$  could lead to its dysregulation. One possibility, among many that could be imagined, is that  $\alpha_v\beta_3$  normally acts as a negative regulator of VEGFR-2 expression and function and ablation of  $\alpha_v\beta_3$  causes upregulation of VEGFR-2 (as we observe). Inhibitors of  $\alpha_v\beta_3$  could then act by causing dysregulation of VEGFR-2. Although beyond the scope of this study, these results raise some important questions. For example, considering the primacy of VEGF/VEGFR-2 signaling in angiogenic processes, the true function of  $\alpha_v\beta_3$  could be to







act as a regulatory balance between inducing and inhibiting angiogenesis.

Here we present strong evidence that  $\beta_3$  and  $\beta_3/\beta_5$ -null mice support and even show enhanced pathological angiogenic responses and tumor growth. Although blocking studies have implicated  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  as having major roles in neovascularization, our findings demonstrate that these integrins are not essential for this process. The efficacy of  $\alpha_v\beta_3$  antagonists in angiogenesis inhibition is not in dispute here—such inhibitors may yet prove to be effective therapeutics. However, our data indicate that a more thorough understanding of the precise mechanisms of action of these inhibitors and of the roles of  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrins in angiogenesis is required.

## Methods

**Antibodies.** Antibodies against VEGFR-2, PECAM, VE-cadherin,  $\alpha_5$  integrin and biotinylated antibodies against  $\beta_3$  integrin were purchased from Pharmingen (Bedford, UK). Rabbit polyclonal antibodies against human  $\beta_3$  and  $\beta_5$  integrins were gifts from B. Coller and L. Reichardt, respectively. Rabbit polyclonal antibody against  $\beta_1$  integrin was as described<sup>42</sup>. Antibody against  $\alpha_v$  integrin was either purchased from Chemicon (Harrow, UK) or for immunofluorescence was a gift from E. Ruoslahti. LM609 was purchased from Chemicon. Antibody against laminin-1 was purchased from Sigma (Poole, UK). Antibody against the heat-shock protein HSC-70 was purchased from Autogen Bioclear (Wiltshire, UK). Conjugated secondary antibodies were purchased from Biosource (Nivelles, Belgium).

**Extracellular matrix reagents.** Fibronectin for cell culture was purchased from Sigma. Rat fibronectin for functional assays was purchased from Gibco BRL (Paisley, UK) and collagen, vitronectin, laminin-1 were obtained from Collaborative Biomedical Research (Bedford, Massachusetts).

**Mouse transplants.** Age- and sex-matched control and integrin-deficient mice on a mixed genetic background (C57BL6/129Sv) were given single s.c. injections of either  $1 \times 10^6$  B16F0 or CMT19T cells and collected ten days after injection ( $n = 9$ –12 mice per group). Rag2- and Rag2/integrin-deficient mice were given single s.c. injections of either  $2 \times 10^6$  LS180 or A375SM cells and collected 3–5 wk after injections ( $n = 3$ –11 mice per group).

**Quantification of blood-vessel density.** Blood-vessel density was quantified by counting the total numbers of PECAM<sup>+</sup>/laminin-1<sup>+</sup> blood vessels across whole sections of tumors ( $n = 3$ –6 per group).

**Primary lung endothelial-cell isolation.** Wild-type and  $\beta_3$ -null mouse lungs were minced, collagenase-digested (Gibco), strained and the resulting cell suspension plated on flasks coated with a mixture of 0.1% gelatin (Sigma), 10 mg/ml fibronectin (Sigma) and 30  $\mu$ g/ml Vitrogen (Collaborative Biomedical Research). Endothelial cells were purified by a single negative (FC $\gamma$ -R1/III antibody; Pharmingen) and two positive (ICAM-2; Pharmingen) cell sorts using anti-rat IgG-conjugated magnetic beads (Dyna, Wiltshire, UK) producing a >97% pure population (J.C.L., unpublished data).

**Immunofluorescence staining.** Subconfluent cultures of endothelial cells and frozen tissue sections were immunostained as described<sup>23</sup>.

**Integrin-surface iodination and immunoprecipitation.** These experiments were carried out as described<sup>42,23</sup>.

**Western blotting.** Wild-type and  $\beta_3$ -null endothelial cells were lysed using RIPA buffer, and 100  $\mu$ g of protein from each lysate were immunoprecipitated using the antibody VEGFR-2 followed by western-blot analysis also using an antibody against VEGFR-2 (ref. 40).

**Cell migration and adhesion assays.** Cell migration<sup>43,23</sup> and adhesion<sup>23</sup> assays were performed as described.

**Hypoxia-induced retinal angiogenesis.** This assay was carried out as described<sup>16</sup> using wild-type and  $\beta_3$ -null mice.

**In vivo Matrigel plug assay.** This assay was carried out as described<sup>44</sup> in wild-type and  $\beta_3$ -null mice. Using 200  $\mu$ l of growth factor-reduced Matrigel (Becton Dickinson, Beds, UK) containing 60 units/ml of heparin (Sigma), mixed with PBS or VEGF (60 ng/ml, R&D Systems, Oxon, UK). Blood-vessel infiltration in 7-day pellets was quantified by analysis of H&E-stained sections using a Zeiss Axioplan microscope.

**Aortic ring assay.** Mouse aortic ring assays were performed essentially as described<sup>45</sup>. 1-mm thoracic aortic rings were placed between 2 layers of 50  $\mu$ l growth factor-reduced Matrigel supplemented with 20 U/ml heparin (Sigma), and overlaid with 100  $\mu$ l of DMEM with or without VEGF (30 ng/ml). Microvessel outgrowth was visualized by phase microscopy and the number of vessels growing from each aortic ring was counted every 2 d using a Zeiss Axioplan microscope.

**FACS analysis.** Wild-type and  $\beta_3$ -null endothelial cells were incubated with VEGFR-2 antibody followed by incubation with a FITC-conjugated secondary antibody. Cells were then analyzed using a Becton Dickinson FACSCalibur flow cytometer.

**Isolation of endothelial cells from transplants.** CMT19T tumors grown subcutaneously in wild-type and  $\beta_3$ -null mice were collected 10 days after injection. Single-cell suspensions were generated by mincing the tumors and digesting them twice for 30 min at 37 °C with a mixture of collagenases (Roche, Lewis, UK; and Gibco). Cell suspensions were stained with an antibody against VE-cadherin (1  $\mu$ g per  $1 \times 10^6$  cells) followed by incubation with antibody against rat IgG-FITC. VE-cadherin<sup>+</sup> cells were sorted using a MoFlo (Cytomation, Friburg, Germany) FACS sorter resulting in a ~90% pure population.  $2 \times 10^6$  VE-cadherin positive endothelial cells were lysed in 200  $\mu$ l RIPA buffer and used for VEGFR-2 immunoprecipitation as described above.

**$\beta_3$  transduction.** The medium from a cell line (E86 $\beta$ 3.1) producing ecotropic retrovirus (gift from J. Marshall) was used to infect endothelial cells with functional human  $\beta_3$  integrin. After 48 h endothelial cells infected with the  $\beta_3$ -integrin virus were selected from the non-infected cells by magnetic bead (Dyna) sorting using the antibody against human  $\alpha_v\beta_3$ , LM609. Cells were lysed and VEGFR-2 was immunoprecipitated followed by western-blot analysis as described. Experiments were repeated 3 times.

**Animal regulations.** All animals were used in accord with United Kingdom Coordination Committee on Cancer Research guidelines and Home Office regulations.

## Acknowledgments

We thank B. Coller, E. Ruoslahti and L. Reichardt for antibodies against mouse  $\beta_3$ ,  $\alpha_v$  and  $\beta_5$  integrin antibodies, respectively; G. Saunders, S. Watling and C. Wren for their technical assistance; G. Elias and colleagues for help with histology; J. Marshall for his gift of human  $\beta_3$ -construct; F. Parkinson for her help in preparing the manuscript; and I. Hart for criticism during this study. This work was supported in part by grants from the NIH (PO1HL41484, PO1HL66105 and RO1CA17007 to R.O.H. and RO1 HL64353, RO1 HL53949 to D.S.), and by the Howard Hughes Medical Institute. R.O.H. is an investigator and D.T. is an Associate of the Howard Hughes Medical Institute.

RECEIVED 31 AUGUST; ACCEPTED 26 NOVEMBER 2001

1. Ferrara, N. & Alitalò, K. Clinical applications of angiogenic growth factors and their inhibitors. *Nature Med.* 5, 1359–1364 (1999).
2. Hynes, R.O., Bader, B.L. & Hodivala-Dilke, K. Integrins in vascular development. *Braz. J. Med. Biol. Res.* 32, 501–510 (1999).
3. Carmeliet, P. & Jain, R.K. Angiogenesis in cancer and other diseases. *Nature* 407, 249–257 (2000).
4. Carmeliet, P. et al. Abnormal blood vessel development and lethality in em-



- bryos lacking a single VEGF allele. *Nature* **380**, 435–439 (1996).
5. Shalaby, F. *et al.* Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. *Nature* **376**, 62–66 (1995).
  6. Fong, G.H., Rossant, J., Gertsenstein, M. & Breitman, M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. *Nature* **376**, 66–70 (1995).
  7. Brekken, R.A. *et al.* Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. *Cancer Res.* **60**, 5117–5124 (2000).
  8. Saariisto, A., Karpanen, T. & Alitalo, K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. *Oncogene* **19**, 6122–6129 (2000).
  9. Senger, D.R. *et al.* Angiogenesis promoted by vascular endothelial growth factor: Regulation through  $\alpha_5\beta_1$  and  $\alpha_5\beta_3$  integrins. *Proc. Natl. Acad. Sci. USA* **94**, 13612–13617 (1997).
  10. Kim, S., Harris, M. & Varner, J.A. Regulation of Integrin  $\alpha_v\beta_3$ -mediated Endothelial Cell Migration and Angiogenesis by Integrin  $\alpha_5\beta_1$  and protein kinase A. *J. Biol. Chem.* **275**, 33920–33928 (2000a).
  11. Brooks, P.C., Clark, R.A.F. & Cheresh, D.A. Requirement of vascular integrin  $\alpha_v\beta_3$  for angiogenesis. *Science* **264**, 569–571 (1994).
  12. Brooks, P.C. *et al.* Integrin  $\alpha_v\beta_3$  antagonists promote tumor regression by inducing apoptosis angiogenic blood vessels. *Cell* **79**, 1157–1164 (1994).
  13. Brooks, P.C. *et al.* Antiintegrin  $\alpha_v\beta_3$  blocks human breast-cancer growth and angiogenesis in human skin. *J. Clin. Invest.* **96**, 1815–1822 (1995).
  14. Drake, C.J., Cheresh, D.A. & Little, C.D. An antagonist of integrin  $\alpha_v\beta_3$  prevents maturation of blood vessels during embryonic neovascularization. *J. Cell Sci.* **108**, 2655–2661 (1995).
  15. Friedlander, M. *et al.* Definition of two angiogenic pathways by distinct  $\alpha_v$  integrins. *Science* **270**, 1500–1502 (1995).
  16. Friedlander, M. *et al.* Involvement of integrins  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  in ocular neovascular diseases. *Proc. Natl. Acad. Sci. USA* **93**, 9764–9769 (1996).
  17. Eliceiri, B.P. & Cheresh, D.A. The role of  $\alpha_v$  integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. *J. Clin. Invest.* **103**, 1227–1230 (1999).
  18. Varner, J.A. & Cheresh, D.A. Integrins and cancer. *Curr. Opin. Cell Biol.* **8**, 724–730 (1996).
  19. Hammes, H.P., Brownlee, M., Jonczyk, A., Sutter, A. & Preissner, K.T. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. *Nature Med.* **2**, 820–820 (1996).
  20. Kumar, C.C. *et al.* Inhibition of angiogenesis and tumor growth by SCH22153, a dual  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  integrin receptor antagonist. *Cancer Res.* **61**, 2232–2238 (2001).
  21. Guthell, J.C. *et al.* Targeted antiangiogenic therapy for cancer using vitaxin: A humanized monoclonal antibody to the integrin  $\alpha_v\beta_3$ . *Clin. Cancer Res.* **6**, 3056–3061 (2000).
  22. Bader, B.L., Rayburn, H., Crowley, D. & Hynes, R.O. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all  $\alpha_v$  integrins. *Cell* **95**, 507–519 (1998).
  23. Hodivala-Dilke, K.M. *et al.*  $\beta_3$ -integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. *J. Clin. Invest.* **103**, 229–238 (1999).
  24. Huang, X.Z., Griffiths, M., Wu, J.F., Farese, R.V. & Sheppard, D. Normal development, wound healing, and adenovirus susceptibility in  $\beta_5$ -deficient mice. *Mol. Cell Biol.* **20**, 755–759 (2000).
  25. Kim, S., Bell, K., Mouse, S.A. & Varner, J.A. Regulation of angiogenesis *in vivo* by ligation of integrin  $\alpha_5\beta_1$  with the central cell-binding domain of fibronectin. *Am. J. Pathol.* **156**, 1345–1362 (2000b).
  26. Pierce, E.A. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity (vol 114, pg 1219, 1996). *Arch. Ophthalmol.* **115**, 427–427 (1997).
  27. Stone, E.M. & Sheffield, V.C. Genetic approaches to human retinal disorders. *Invest. Ophthalmol. Vis. Sci.* **37**, 3100–3100 (1996).
  28. Kroon, M.E., Koolwijk, P., van der Vecht, B. & van Hinsbergh, V.W.M. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: Implications for capillary-like tube formation in a fibrin matrix. *Blood* **96**, 2775–2783 (2000).
  29. DiazGonzalez, F., Forsyth, J., Steiner, B. & Ginsberg, M.H. Trans-dominant inhibition of integrin function. *Mol. Biol. Cell* **7**, 1939–1951 (1996).
  30. Blystone, S.D., Graham, I.L., Lindberg, F.P. & Brown, E.J. Integrin  $\alpha_v\beta_3$  differentially regulates adhesive and phagocytic functions of the fibronectin receptor  $\alpha_5\beta_1$ . *J. Cell Biol.* **127**, 1129–1137 (1994).
  31. Huhtala, P. *et al.* Cooperative signalling by  $\alpha_5\beta_1$  and  $\alpha_v\beta_1$  integrins regulates metalloproteinase gene expression in fibroblasts adhering to fibronectin. *J. Cell Biol.* **129**, 876–879 (1995).
  32. Chen, Y. *et al.* "Inside out" signal transduction inhibited by isolated integrin cytoplasmic domains. *J. Biol. Chem.* **269**, 18307–18310 (1994).
  33. LaFlamme, S.E., Thomas, L.A., Yamada, S.S. & Yamada, K.M. Single subunit chimeric integrins as mimics and inhibitors of endogenous integrin functions in receptor localization, cell spreading and migration, and matrix assembly. *J. Cell Biol.* **126**, 1287–1298 (1994).
  34. Taverna, D. & Hynes, R.O. Reduced blood vessel formation and tumor growth in  $\alpha_5$ -integrin-negative teratocarcinomas and embryoid bodies. *Cancer Res.* **61**, 5255–5261 (2001).
  35. Asahara, T. *et al.* VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. *EMBO J.* **18**, 3964–3972 (1999).
  36. Isner, J.M. & Asahara, T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. *J. Clin. Invest.* **103**, 1231–1236 (1999).
  37. Kalka, C. *et al.* Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. *Proc. Natl. Acad. Sci. USA* **97**, 3422–3427 (2000).
  38. Takahashi, T. *et al.* Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nature Med.* **5**, 434–438 (1999).
  39. Carmeliet, P. *et al.* Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. *Nature Med.* **7**, 575–583 (2001).
  40. Soldi, R. *et al.* Role of  $\alpha_v\beta_3$  integrin in the activation of vascular endothelial growth factor receptor-2. *EMBO J.* **18**, 882–892 (1999).
  41. Byzova, T.V. *et al.* A mechanism for modulation of cellular responses to VEGF: Activation of the integrins. *Mol. Cell* **6**, 851–860 (2000).
  42. Marcantonio, E. & Hynes, R. Antibodies to the conserved cytoplasmic domain of the integrin  $\beta_1$  subunit react with proteins in vertebrates, invertebrates, and fungi. *J. Cell Biol.* **106**, 1765–1772 (1988).
  43. Albrecht-Buehler, G. The phagokinetic tracks of 3T3 Cells. *Cell* **11**, 395–404 (1977).
  44. Passaniti, A. *et al.* A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. *Lab. Invest.* **67**, 519–528 (1992).
  45. Nicosia, R.F. & Ottinetti, A. Modulation of microvascular growth and morphogenesis by reconstituted basement-membrane gel in 3-dimensional cultures of rat aorta—a comparative study of angiogenesis in Matrigel, collagen, fibrin, and plasma clot. *In Vitro Cell. Dev. Biol.* **26**, 119–128 (1990).